FDA Approval of Senseonics Eversense® CGM for Use for Up to 6 Months
FDA approves Senseonics Eversense® E3, the first long-term implantable CGM system, and the E3 includes technology that extends the use…
100 Years, 100 Breakthrough T1D Scientists: The BB Rat—An Animal Model of Type 1 Diabetes
In 1974, a colony of non-diabetic BB rats develops diabetes. Examination of their pancreases revealed that they had no beta…
The First Gene-Edited Cell Replacement Therapy Takes a Step Forward
The first person has received ViaCyte and CRISPR's cell replacement therapy.
FDA Authorizes a Fourth Artificial Pancreas System
The FDA authorized the Insulet Omnipod 5, the world’s first tubeless, wearable system for people 6 and older, using an…
Interview with our New Community Screening and Clinical Trial Education Director
Breakthrough T1D has a new community screening and clinical trials education director. She's been a volunteer and now staff since…
New Study Shows Kids 1+ Benefit from Artificial Pancreas Technology
A new paper published in the New England Journal of Medicine shows hybrid closed loop systems help children as young…
100 Years, 100 Breakthrough T1D Scientists: Gian Franco Bottazzo, M.D.
In honor of the 100th anniversary of insulin, we are launching “100 Years, 100 Breakthrough T1D Scientists.” The first up:…
CDC Study: Children Who Have Recovered from COVID-19 May Be at Increased Risk of Diabetes
CDC researchers report an apparent association between pediatric COVID-19 and diabetes diagnoses.
Insulin: A Story of Innovation
On January 11, 1922—100 years ago—14-year-old Leonard Thompson, who was diagnosed with diabetes 3 years earlier, became the first person…
Celebrating the Best of 2021
In 2021, Breakthrough T1D has seen tremendous progress in accelerating cures, improving lives, and advocating for people with type 1…
